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Optimal Elevation of b-Cell 11b-Hydroxysteroid
Dehydrogenase Type 1 Is a Compensatory Mechanism
That Prevents High-Fat Diet–Induced b-Cell Failure
Sophie Turban,1 Xiaoxia Liu,1 Lynne Ramage,1 Scott P. Webster,2 Brian R. Walker,2 Donald R. Dunbar,3
John J. Mullins,4 Jonathan R. Seckl,2 and Nicholas M. Morton1
Type 2 diabetes ultimately results from pancreatic b-cell failure.
Abnormally elevated intracellular regeneration of glucocorti-
coids by the enzyme 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) in fat or liver may underlie pathophysiological aspects
of the metabolic syndrome. Elevated 11b-HSD1 is also found in
pancreatic islets of obese/diabetic rodents and is hypothesized
to suppress insulin secretion and promote diabetes. To deﬁne the
direct impact of elevated pancreatic b-cell 11b-HSD1 on insulin
secretion, we generated b-cell–speciﬁc, 11b-HSD1–overexpressing
(MIP-HSD1) mice on a strain background prone to b-cell failure.
Unexpectedly, MIP-HSD1tg/+ mice exhibited a reversal of high fat–
induced b-cell failure through augmentation of the number and
intrinsic function of small islets in association with induction
of heat shock, protein kinase A, and extracellular signal–related
kinase and p21 signaling pathways. 11b-HSD12/2 mice showed
mild b-cell impairment that was offset by improved glucose
tolerance. The beneﬁt of higher b-cell 11b-HSD1 exhibited a thresh-
old because homozygous MIP-HSD1tg/tg mice and diabetic Lepdb/db
mice with markedly elevated b-cell 11b-HSD1 levels had impaired
basal b-cell function. Optimal elevation of b-cell 11b-HSD1 rep-
resents a novel biological mechanism supporting compensatory
insulin hypersecretion rather than exacerbating metabolic dis-
ease. These ﬁndings have immediate signiﬁcance for current
therapeutic strategies for type 2 diabetes. Diabetes 61:642–
652, 2012
Type 2 diabetes prevalence has risen dramaticallyin parallel with the worldwide increase in obesity(1). Understanding and targeting the processesleading to b-cell exhaustion in the face of pe-
ripheral insulin resistance is therefore of major importance.
Glucocorticoid hormones potently regulate metabolism
and, in rare cases of excess (Cushing syndrome), cause
metabolic syndrome (2). Elevated local tissue glucocorti-
coid excess, driven by increased levels of the intracellular
glucocorticoid regenerating enzyme 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1), particularly in adipose
tissue, is implicated in the development of idiopathic met-
abolic syndrome (3). This premise is strongly supported by
the phenotype of transgenic mice overexpressing 11b-HSD1
in fat or liver, which recapitulates diabetes and insulin-
resistant metabolic disease, and by the protection from
metabolic disease exhibited by 11b-HSD12/2 mice (3).
11b-HSD1 is also found in pancreatic islets (4). 11b-
HSD1 is elevated in islets of diabetic rodents (4–6), where
it was hypothesized to promote b-cell failure by amplifying
the suppressive effects of glucocorticoids on insulin secre-
tion (7,8). Although this strengthens the growing contention
that 11b-HSD1 inhibitors are an effective therapeutic treat-
ment for metabolic syndrome through actions in multiple
organ systems (9), any physiological role of b-cell 11b-HSD1,
and indeed the potentially pathogenic role (5–8) of ele-
vated 11b-HSD1 in islets in vivo, remains uncertain. To
test the hypothesis that increased b-cell 11b-HSD1 is di-
abetogenic, we used the insulin-I promoter (10) to drive
b-cell–speciﬁc 11b-HSD1 elevation in vivo in C57Bl/KsJ
mice, a strain prone to high-fat (HF) diet–induced b-cell
failure (11).
RESEARCH DESIGN AND METHODS
Animals. All experiments conformed to local ethical guidelines and the
Home Ofﬁce (U.K.) Animals Scientiﬁc Procedures Act (1986). Male C57BL/KsJ,
C57BL/6J (The Jackson Laboratory, Bar Harbor, ME), BKS.Cg+Leprdb/+Leprdb/
OlaHsd (Lepdb/db) (Harlan, Bicester, U.K.), and inbred C57BL/6J-11b-HSD12/2
mice were housed as previously described (12). Mice were fed an HF diet
(D12331; Research Diets, New Brunswick, NJ) or control diet (CD) (D12328)
for 12 weeks from 4 weeks of age.
Generation of MIP-rHSD1 transgenic mice. An 8.3-kb (HindIII [28280]/
NotI [+12]) fragment of the mouse insulin gene promoter I (MIP) (gift of Mark
Magnusson, Vanderbilt University, Nashville, TN) (10) and the 1.265-bp EcoRI
fragment of the rat 11b-HSD1 (rHSD1) were cloned into pGEM11Zf(+) to
create the MIP-rHSD1 transgene. The MIP-rHSD1 (10.2 kb) transgene was
removed with HindIII/SﬁI and microinjected into the pronuclei of fertilized
oocytes from C57BL/KsJ mice by standard techniques (Genetic Intervention
and Screening Technologies, University of Edinburgh). The transgene was
detected by PCR on tail genomic DNA using primer sequences: MIP-rHSD1,
59-GGAACTGTGAAACAGTCCAAGG-39 and 59-TTTGCTGGCCCCAGTGACAA-
GCTTT-39; HSD1, 59-AAAGCTTGTCACTGGGGCCAGCAAA-39 and 59-AGGAT-
CCAGAGCAAACTTGCTTGCA-39; and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 59GCCAAGGTCATCCATGACAAC and 59-AGTGTAGCCCAAGAT-
GCCCTT-39. The mice were genotyped by Southern blotting analysis of ge-
nomic DNA using AﬂIII digestion and [a-32P]d-CTP–labeled rHSD1 cDNA.
Transgenic heterozygotes MIP-HSD1tg/+ were maintained on the C57BL/KsJ
genetic background, and littermate wild-type C57BL/KsJ mice were used as
controls.
Transgene expression. 11b-HSD1 activity was tested in rat INS1E cells (a
gift of C. Wollheim, University of Geneva, Geneva, Switzerland) and mouse
MIN6 cells (a gift of G. Rutter, Imperial College London, London, U.K.) 48 h
after MIP-rHSD1 lipofection (Invitrogen, Paisley, U.K.).
Islet isolation and preparation. Pancreata were digested with collagenase
XI (Sigma-Aldrich, Dorset, U.K.), and islets were hand-picked under a
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stereomicroscope in Hanks’ balanced salt solution and 10% FBS (Lonza,
Berkshire, U.K.). For 11b-HSD1 activity assay (13), batches of 100 islets/cell
lines were incubated in RPMI 1640 medium, 10% FBS, and 2.8, 16.8, or 5.5 mmol/L
glucose for 24 h. For RNA extraction, islets were directly homogenized in TRIzol
reagent (Life Technologies, Paisley, U.K.). For insulin secretion studies, batches
of 10 islets were allowed to rest (2 h) in basal Krebs (1% weight for volume [w/v]
BSA fraction V, 2.8 mmol/L glucose) on 8-mm inserts (Millipore, Billerica, MA)
suspended in 12-well culture dishes. Samples were collected every 5 or 10 min
for discrimination of the basal and glucose-stimulated (16.8 mmol/L glucose)
insulin secretion (GSIS). A return to 2.8 mmol/L veriﬁed speciﬁcity of the
response. For membrane-proximal secretion analysis, islets were preincu-
bated (2 h) with 0.5 mg/ml brefeldin A (BFA) and 15 mmol/L cycloheximide
(CHX) (Applichem, Darmstadt, Germany) and then incubated for 30 min in
basal Krebs. For potassium-stimulated insulin secretion (PSIS), islets were
preincubated (2 h) in basal Krebs for 30 min and then for 30 min with 40 mmol/L
KCl. Acute (2 h) steroid effects (20 or 200 nmol/L 11-dehydrocorticosterone
[11-DHC]) were investigated using Krebs and the 11b-HSD1 inhibitor UE2316
(1 mmol/L) or the glucocorticoid receptor (GR) antagonist RU486 (1 mmol/L).
Fatty acid effects were investigated using RPMI 1640 medium, 5.5 mmol/L
glucose, 10% FBS, 1% BSA, 20 nmol 11-DHC, with or without 0.5 mmol/L pal-
mitate (22 h) followed by equilibration in Krebs (2 h) and then 2.8 mmol/L
(30 min) and 16.8 mmol/L (30 min) incubations. Insulin was measured by ra-
dioimmunoassay (Linco Research, St. Charles, MO).
RNA extraction and gene expression analysis. Isolated islet total RNA was
puriﬁed using PureLink RNA micro kit (Invitrogen, Paisley, U.K.). Random-
primed cDNA was synthesized using Superscript III reverse transcriptase
(Invitrogen). For real-time PCR, cDNA was mixed with light cycler 480 probes
master mix (Roche Diagnostics, Indianapolis, IN) and probes of interest: mouse
b-actin, 4352933E; Cdkn1a, Mm00432448_1; Prkacb, Mm00440840_1; Braf,
Mm01165837_1; Hspa1b, Mm03038954_s1; HSD11b1, Mm00476182-m1; TBP,
Mm00446973-m1 (Applied Biosystems, Warrington, U.K.).
Microarray analysis. Total islet RNA was processed through standard
Affymetrix Mouse Genome 430-2.0 GeneChip protocols (ARK Genomics, Roslin
Institute, Edinburgh, U.K.). Data were extracted through the GCOS software,
and CEL ﬁles were imported into Bioconductor, normalized by RMA in the
Affy module, and statistically analyzed with the Limma and Rank products
(RankProd) packages. Gene ontology and Kyoto Encyclopedia of Genes and
Genomes pathway enrichment analysis was done with the DAVID tool. Data are
available in the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE23161.
Intravenous glucose tolerance test. Mice were anesthetized by intra-
peritoneal injection of 1 mg/mL medetomidine (Domitor) and 100 mg/mL
ketamine (Vetalar) (0.1 mL/10 g body weight). The right jugular vein was
cannulated with microrenathane tubing (0.25 inch outer diameter 3 0.012 inch
inner diameter; Sandown Scientiﬁc, Hampton, U.K.). The cannula was exte-
riorized on the back of the neck and mice were allowed to recover for 2 days.
Mice were fasted for 4 h before saline (0.2 ml/min, 2 h) and then glucose (25%
w/v) was infused (10 ml/min/30 g body weight) into the mice (CMA/102
microdialysis pump; CMA Microdialysis, Solna, Sweden). Glucose infusion
was stopped at 60 min. At 0, 1, 3, 5, 10, 15, 30, 60, and 120 min, blood glucose
was measured using a OneTouch Ultra (Johnson and Johnson, Bucks, U.K.).
Insulin was measured by ELISA (CrystalChem, Chicago, IL).
Intraperitoneal glucose tolerance test. Mice were fasted for 6 h and then
injected intraperitoneally with 2 mg/g body wt. D-glucose (25% v/w). Blood was
sampled at 0, 2, 5, 10, 15, 30, 60, and 120-min intervals after glucose bolus.
Blood glucose was determined using Inﬁnity reagent (Thermotrace, Leeds,
U.K.) and insulin by ELISA (CrystalChem).
Blood corticosterone level. Singly housed mice were sampled by venesec-
tion at 8:00 A.M. within 1 min of cage disturbance. Plasma corticosterone levels
were measured by radioimmunoassay as previously described (12).
Plasma triglyceride and nonesteriﬁed fatty acid levels. Triglyceride (In-
ﬁnity; Thermo Fisher Scientiﬁc, Middletown, VA) and nonesteriﬁed fatty acid
(NEFA) (Wako, Richmond, VA) were measured in plasma of fed or 6-h fasted
mice after tail venesection.
Western blotting. Batches of 60 islets were incubated in RPMI 1640 medium
(11.1 mmol/L glucose) and 10% FBS for 24 h with or without 1 mmol/L UE2316
11b-HSD1 inhibitor or 5 mmol/L KT5720 cAMP-dependent protein kinase
(PKA) phosphorylation inhibitor (Sigma-Aldrich). Islets were homogenized in
lysis buffer (50 mmol/L Tris, pH 7.4, 0.27 mol/L sucrose, 1 mmol/L sodium
orthovanadate, pH 10, 1 mmol/L EDTA, 1 mmol/L EGTA, 10 mmol/L sodium
b-glycerophosphate, 50 mmol/L NaF, 5 mmol/L sodium pyrophosphate, 1% [w/v]
Triton X-100, 0.1% [v/v] 2-mercaptoethanol, one tablet of complete TM pro-
tease inhibitor [Roche, Burgess Hill, U.K.]) and subjected to Western blotting.
Primary antibodies were anti-PKAbcat (1:1,000) (Santa Cruz Biotechnology,
Santa Cruz, CA), anti–phospho-ERK thr202 tyr204 (1:1,000), anti-ERK1/2 na-
tive (1:1,000), and anti–b-actin (1:1,000) (Cell Signaling Technologies, Beverley,
U.K.). HRP–anti-rabbit IgG (1:1,000) was used as a secondary antibody with
enhanced chemiluminescence (Amersham, Little Chalfont, U.K.) and exposure
to Amersham HyperﬁlmTH ECL autoradiographic ﬁlm (Amersham). Blots
were quantiﬁed using ImageJ software (www.ncbi.nlm.nih.gov).
Optical projection tomography. Optical projection tomography (OPT) was
performed on whole pancreata (14) using an OPT scanner (Bioptonics 3001;
Skyscan, Kontich, Belgium) and images were analyzed with Data Viewer
version 1.3.2 (Bioptonics).
Immunostaining. Whole pancreata were ﬁxed (4% paraformaldehyde), wax
embedded, and sectioned (5 mm) before being immunostained with sheep
anti-HSD1 antibody (13). For chromogen labeling with diaminobenzidine
(DakoCytomation, Inc, Carpinteria, CA), biotinylated anti-sheep (Abcam, plc,
Cambridge, U.K.) was used as secondary antibodies. Images were processed
using KS3000 software (version 3.0; Carl Zeiss Vision, GmbH).
Immunoﬂuorescence staining. Frozen sections (5 mm) of whole pancreata
or single cells from trypsin-digested islets were ﬁxed in acetone:methanol
(90:10 v/v) and immunostained using guinea pig anti-insulin, sheep anti–11b-
HSD1 antibody (13), rabbit anti-glucagon, somatostatin, pancreatic poly-
peptide (Chemicon; Millipore, Billerica, MA), and Cy2-conjugated AfﬁniPure F
(ab’)2 fragment donkey anti–guinea pig IgG, rhodamine red X–conjugated
AfﬁniPure F(ab’)2 fragment donkey anti-sheep, ﬂuorescein isothiocyanate–
conjugated AfﬁniPure F(ab’)2 fragment donkey anti-sheep, and rhodamine red
X–conjugated AfﬁniPure F(ab’)2 fragment donkey anti-rabbit (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA) were used as secondary
antibodies. Images were taken using a Leica confocal microscope linked to LSM
Image Browser software.
Insulin content. Whole pancreata were homogenized in lysis buffer, and
insulin was extracted with acid ethanol and measured by radioimmunoassay
(Linco Research). Insulin was normalized to total protein content (Bio-Rad
Laboratories, Hercules, CA).
Statistics. Data are expressed as mean6 SEM and were analyzed by unpaired
Student t test, one-way ANOVA Newman-Keuls, or two-way ANOVA.
RESULTS
Generation of b-cell–speciﬁc 11b-HSD1 overexpres-
sion model. The rat 11b-HSD1 cDNA was cloned down-
stream of the mouse insulin I promoter (Fig. 1A) that drives
highly b-cell–speciﬁc expression (10,15). The construct was
validated by demonstrating increased 11b-HSD1 activity
after transfection into clonal INS1E and MIN6 cells (Sup-
plementary Fig. 1A and B). Transgenic mice were generated
on the b-cell, failure-susceptible C57BL/KsJ (KsJ) strain
background (11). Southern blotting suggested integration
of a low copy number (approximately two) of the transgene
(Fig. 1B). In MIP-HSD1tg/+ islets, 11b-HSD1 mRNA was in-
creased eightfold (Fig. 1C). 11b-HSD1 protein was elevated
speciﬁcally in b-cells of MIP-HSD1 transgenics (Fig. 1D and
Supplementary Fig. 2). Note that 11b-HSD1 is expressed
in b-cells of normal islets, as shown by the colocalization
with insulin-positive cells and in other islet cell subtypes
(Supplementary Fig. 3), as found by others (16). 11b-HSD1
reductase (glucocorticoid reactivation) activity was approx-
imately twofold higher in isolated primary MIP-HSD1tg/+
islets than littermate control islets and was glucose in-
ducible (Fig. 1E). Hexose-6-phosphate dehydrogenase level,
which drives 11b-reductase activity (17), was not limiting.
11b-HSD1 dehydrogenase (glucocorticoid inactivating) ac-
tivity was 10-fold lower than reductase in islets and was
unaffected by transgene or high glucose (Supplementary
Fig. 1C and D). MIP-HSD1tg/+ mice were viable and appeared
grossly normal (Table 1). Fasting plasma insulin, glucose
triglyceride, and NEFA levels were unaffected by geno-
type (Table 1), indicating similar peripheral insulin sensi-
tivity and b-cell exposure to lipotoxicity with HF.
MIP-HSD1tg/+ mice are protected fromHF diet–induced
b-cell failure. To determine transgene impact in vivo,
mice were fed an HF diet for 12 weeks to induce b-cell
failure (11). Plasma corticosterone levels were not signiﬁ-
cantly affected by diet or genotype (Table 1), indicating
that transgene effects were b-cell speciﬁc and not due to
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hypothalamic-pituitary-adrenal disturbance. To accurately
assess insulin secretion, especially over the rapid response
of the ﬁrst phase (1–10 min), glucose was infused through a
jugular cannula. CD-fed animals had comparable responses
to glucose infusion (Fig. 2A and C). HF-fed KsJ mice, as
expected (11), showed markedly attenuated GSIS indicative
of b-cell failure and an associated prolonged elevation of
plasma glucose levels in vivo (Fig. 2B and C). In contrast,
HF-fed MIP-HSD1tg/+ mice exhibited profoundly elevated
ﬁrst- and second-phase GSIS that completely normalized
glucose levels (Fig. 2B and C).
MIP-HSD1tg/+ mice have increased adult islet number.
Protective MIP-HSD1tg/+ compensatory hyperinsulinemia
can occur through two major pathways: increased b-cell
number (neogenesis, b-cell replication, and reduced apo-
ptosis) and increased b-cell function (insulin output per
b-cell). To address b-cell/islet number, whole pancreas islet
number was quantiﬁed by OPT (14) (Fig. 3A and B) and
validated by conventional immunohistochemistry in pan-
creas sections (Fig. 3C). MIP-HSD1tg/+ had more islets (Fig.
3A–C) of smaller dimensions compared with littermates on
control and HF diet (Fig. 3D). Average islet size increased
FIG. 1. Validation of the MIP-HSD1 transgenic model. A: Schematic representation of the MIP-HSD1 transgene. B: Germline transmission was
conﬁrmed using PCR of tail DNA using MIP-HSD1–speciﬁc primers and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal
control. The left panel shows PCR bands in pMIP-HSD1 plasmid control and MIP-HSD1 DNA, but not KsJ genomic DNA. The right panel shows
Southern analysis with clear signal from endogenous 11b-HSD1 (lower bands) and the MIP-HSD1 transgene (upper bands). Copy number was two
to four in MIP-HSD1tg/+. C: 11b-HSD1 mRNA levels measured by real-time PCR in isolated islets of either KsJ or MIP-HSD1tg/+; n = 8. ***P < 0.001.
D: Representative immunohistochemistry images showing 11b-HSD1 localization in islets from KsJ and MIP-HSD1tg/+ mice. Original magniﬁcation
340. E: 11b-HSD1 activity assayed in isolated islets from KsJ and MIP-HSD1tg/+ mice treated with low (2.8 mmol/L) or high (16.8 mmol/L) glucose
concentrations expressed as nanomoles of 11-DHC [A] metabolized into corticosterone [B] after 24 h. ***P < 0.001, MIP-HSD1tg/+ 16.8 mmol/L vs.
KsJ 16.8 mmol/L; n = 6. †P < 0.05, MIP-HSD1tg/+ 16.8 mmol/L vs. MIP-HSD1tg/+ 2.8 mmol/L; n = 6. a.u., arbitrary units. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
TABLE 1
Physiological parameters of MIP-HSD1 mice
KsJ CD KsJ HF MIPtg/+ CD MIPtg/+ HF MIPtg/tg CD MIPtg/tg HF
Body weight (g) 29.1 6 0.36 30.0 6 0.38 30.0 6 0.39 29.5 6 0.42 30.2 6 0.4 29.2 6 0.3
Food intake (kcal/mice/day) 12.8 6 3.1 11.1 6 1.5 13.2 6 2.0 11.9 6 0.8 10.2 6 1.3 11.8 6 1.0
Epididymal mass (mg/g body weight) 19.5 6 1.9 28.3 6 1.8** 17.1 6 1.4 23.8 6 1.7* 14.2 6 1.4 22.6 6 1.3*
Liver mass (mg/g body weight) 46.6 6 1.4 44.2 6 1.3 40.8 6 2.1 45.1 6 1.6 39.4 6 2.16 41 6 2.3
Fasting glucose (mmol/L) 5.4 6 0.32 5.6 6 0.48 4.89 6 0.6 5.2 6 0.24 5.3 6 0.3 5.25 6 0.3
Fasting insulin (ng/mL) 0.85 6 0.33 0.48 6 0.27 0.56 6 0.11 0.74 6 0.33 0.56 6 0.35 0.43 6 0.17
Fasting NEFA (mmol/L) 0.94 6 0.04 1.27 6 0.18 1.10 6 0.10 1.48 6 0.20 1.08 6 0.12 1.18 6 0.05
Fed NEFA (mmol/L) 0.33 6 0.06 0.68 6 0.06** 0.34 6 0.06 0.58 6 0.07* 0.27 6 0.04 0.67 6 0.14*
Fasting triglyceride (mmol/L) 0.97 6 0.03 0.94 6 0.03 0.88 6 0.02 0.89 6 0.02 0.96 6 0.01 0.93 6 0.01
Fed triglyceride (mmol/L) 0.97 6 0.05 1 6 0.05 0.92 6 0.02 0.91 6 0.02 0.86 6 0.02 0.94 6 0.02
Corticosterone level (ng/mL) 6.87 6 1.5 9.46 6 2.2 4.98 6 0.9 9.60 6 1.4 4.49 6 0.6 5.11 6 0.7
Data are mean 6 SEM. Body weight, food intake, tissue weights, fasting glucose, insulin, fasting and fed triglycerides, NEFA, and morning
corticosterone levels in 3-month-old male KsJ, MIP-HSD1tg/+, and MIP-HSD1tg/tg mice after 12 weeks on CD or HF diet. *P , 0.05 vs. CD; n =
9–12. **P , 0.01 vs. CD; n = 9–12.
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in KsJ mice with chronic HF, indicating selective loss
of small functional islets (Fig. 3A–D), a process driven
at least in part by apoptosis (18), whereas MIP-HSD1tg/+
mice showed attenuation of b-cell loss. b-Cell replication
(as indicated by Pdx1 and Ki67 costaining) was unaltered
in MIP-HSD1tg/+ transgenics (Supplementary Fig. 4). The
insulin promoter is expressed at an early stage of pancreatic
islet development (19) when increased glucocorticoid
exposure reduces b-cell mass (20). This would predict, if
anything, lower islet mass in MIP-HSD1tg/+ mice. How-
ever, the MIP-HSD1 transgene had no discernible effect
on the development of the endocrine pancreas (OPT in
fetal day E18 islet bodies and newborn pancreas) (Sup-
plementary Fig. 5), suggesting that a postnatal regulatory
FIG. 2. Reversal of b-cell failure in MIP-HSD1tg/+ mice in vivo. A: CD-fed KsJ and MIP-HSD1tg/+ mice were infused with glucose (83 mg/min/g) for 1 h
intravenously to test dynamic ﬁrst- and second-phase b-cell insulin secretion (left) and associated glycemia (right) in vivo. B: Data for HF-fed KsJ
and MIP-HSD1tg/+ mice as in A. *P < 0.05; **P < 0.01, between MIP-HSD1tg/+ HF vs. HF KsJ. C: Area under the curve for insulin (left) and glucose
(right). ***P < 0.001, MIP-HSD1tg/+ HF vs. KsJ HF. †††P < 0.001, MIP-HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. ##P < 0.01, KsJ HF vs. KsJ CD. *P < 0.05,
between MIP-HSD1tg/+ HF vs. KsJ HF. n = 6–9. A.U., arbitrary units.
S. TURBAN AND ASSOCIATES
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FIG. 3. Augmented islet number and function in HF-fed MIP-HSD1tg/+ mice. A: Representative OPT images of whole pancreas from KsJ and MIP-
HSD1tg/+ mice after 12 weeks on CD or HF diet. Insulin ﬂuorescent immunostaining is represented by red coloring. B: Quantiﬁcation by OPT of
insulin-positive islets per whole pancreas in KsJ and MIP-HSD1tg/+ mice on CD or HF diet. *P < 0.05, KsJ CD vs. KsJ HF. ††P < 0.01, MIP-HSD1tg/+
CD vs. KsJ CD. ###P < 0.001, MIP-HSD1tg/+ HF vs. KsJ HF. n = 4–6. C: The OPT method was validated by determining the ratio of islet number per
pancreatic surface area in pancreatic sections immunostained for insulin. *P < 0.05, KsJ CD vs. KsJ HF. ##P < 0.01, MIP-HSD1tg/+ HF vs. KsJ HF.
†P < 0.05, MIP-HSD1tg/+ vs. KsJ CD. n = 15–20 sections per pancreas; n = 12–15 mice per group. D: Islet size (ratio of islet area to total pancreatic
surface area; mm2) in pancreatic sections immunostained for insulin. ***P < 0.001, KsJ CD vs. KsJ HF. †P < 0.05, MIP-HSD1tg/+ CD vs. KsJ CD.
###P < 0.001, MIP-HSD1tg/+ HF vs. KsJ HF. §§P < 0.01, MIP-HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. n = 20–15 sections per pancreas; n = 15–20 mice per
group. E: GSIS from batches of 10 size-matched islets from CD-fed (left) or HF-fed (right) KsJ and MIP-HSD1tg/+ mice exposed to 2.8 mmol/L and
then 16.8 mmol/L glucose. *P< 0.05, MIP-HSD1tg/+ HF vs. KsJ HF (n = 6). F: Basal insulin secretion by islets from KsJ and MIP-HSD1tg/+ mice on CD
or HF diet were preincubated for 2 h in 2.8 mmol/L glucose with or without 0.5 mg/mL BFA and 15 mmol/L CHX and then incubated for 30 min with
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mechanism drives increased islet number in MIP-HSDtg/+
mice.
MIP-HSD1tg/+ mice have augmented islet-autonomous
secretory function. To test the additional possibility of
enhanced islet insulin secretory function, we measured GSIS
in carefully size-matched (average diameter 100 mm) iso-
lated islets in vitro. In agreement with the ﬁndings in vivo,
isolated islets from CD-fed KsJ and MIP-HSD1tg/+ mice
showed similar GSIS (Fig. 3E, left), whereas islets from HF-
fed MIP-HSD1tg/+ mice exhibited augmented GSIS (Fig. 3E,
right).
MIP-HSD1tg/+ islets have augmented membrane-proximal
secretory capacity. We next investigated whether the
insulin secretory machinery was speciﬁcally enhanced in
MIP-HSD1tg/+ islets. To assess this, insulin translation and
Golgi trafﬁcking was inhibited with CHX and brefeldin A
(BFA), revealing relatively enhanced basal (unregulated)
insulin secretion from islets of MIP-HSD1tg/+ mice on HF
compared with control-fed mice (Fig. 3F). In addition, PSIS
(glucose independent, membrane proximal) was signiﬁ-
cantly higher from islets of HF-fed MIP-HSD1tg/+ compared
with HF-fed KsJ mice (Fig. 3G), consistent with a larger
pool of secretory granules and/or a faster rate of exocytosis
in islets of MIP-HSD1tg/+ mice on HF.
11b-HSD1/glucocorticoid–dependent effects on islet
function are dose sensitive. To conﬁrm glucocorticoid
and 11b-HSD1 dependence of the transgene, islets were
incubated acutely (2 h) in 20 nmol/L (;physiological) or
200 nmol/L (supraphysiological) 11-DHC. GSIS was sig-
niﬁcantly higher from islets from HF MIP-HSD1tg/+ mice
exposed to 20 nmol/L 11-DHC, and this was abolished by
the 11b-HSD1 inhibitor UE2316 (Supplementary Table 1)
and the GR antagonist RU486. Supraphysiological 11-
DHC completely blunted GSIS, as mentioned by others
(4,6,16). Inhibition was also reversed in islets of HF-fed
MIP-HSD1tg/+ mice by 11b-HSD1 and GR inhibitors.
Palmitate-stimulated GSIS is augmented inMIPHSD1tg/+
islets in vitro. Fatty acids augment insulin secretion in
the short term. To investigate the role of elevated b-cell
11b-HSD1 in this process, palmitate-stimulated GSIS was
assessed in isolated islets from MIP-HSD1tg/+ after 24 h
exposure to 20 nmol/L 11-DHC. Notably, long-term static
exposure of islets to 20 nmol/L 11-DHC alone impaired
insulin release in vitro (Supplementary Fig. 8). Palmitate-
stimulated GSIS from MIP-HSDtg/+ was reversed by 11b-
HSD1 and GR inhibitors (Supplementary Fig. 8), suggesting
a role for 11b-HSD1 in fatty acid–stimulated GSIS.
MIP-HSD1tg/+ islets show induction of genes of differ-
entiation, secretory pathways, and cellular stress
management. To better understand the mechanisms of
improved islet function in HF-fed MIP-HSD1tg/+ mice, we
performed a comparative transcriptomic analysis (Sup-
plementary Table 2). MIP-HSD1tg/+ islets had higher mRNA
levels for genes of the small GTPase pathway (Arf6, Prkacb,
and PKA catalytic subunit b [PKAbcat]) linked to enhanced
insulin secretion and islet survival (21–23), protein traf-
ﬁcking, turnover, and vesicle docking (VapB and C, Arf6,
cplx2, and stx11), consistent with the enhanced secretory
responses (Fig. 3E, right, and F and G) and the mitogen-
activated protein kinase/extracellular signal–related ki-
nase (ERK) (B-raf, Max, and Cdkn1a/p21) and Jak/Stat
pathways (Ccnd2 and Jak1), indicative of maintained dif-
ferentiation versus proliferation commitment (24–27) and
protection from apoptosis (28,29). MIP-HSD1tg/+ islets also
exhibited higher mRNA levels of genes related to pro-
tection from cellular stress (hspa1a, -a1b, -a4, and trib3)
(30). Key gene expression changes were validated by real-
time PCR (Fig. 4A–D). Interestingly, Cdkn1a gene expression
was downregulated in islets of KsJ mice on HF (Fig. 4D),
consistent with HF-induced cellular stress, apoptosis (29),
and islet loss (Fig. 3A–C), whereas Cdkn1a was upregulated
by HF in MIP-HSD1tg/+, consistent with maintained func-
tionality with reduced cellular stress.
MIP-HSD1tg/+ islets exhibit elevated PKA and ERK
signaling. To test whether the validated gene expression
changes had a functional impact upon islet responses,
we investigated two key pathways linked to enhanced in-
sulin secretion (PKA) and downstream cell differentiation/
survival pathways (ERK). Protein levels of the catalytic
subunit of PKA (PKAbcat) were markedly induced in islets
from HF diet–fed MIP-HSD1tg/+ mice (Fig. 4E), and this was
reversed with the 11b-HSD1 inhibitor UE2316 (Fig. 4F) but
not the PKA phosphorylation inhibitor KT5720 (Fig. 4G).
Likewise, activation (phosphorylation) of the ERK signal-
ing pathway was enhanced in MIP-HSD1tg/+ islets (Fig. 4H).
Induction of ERK activation in MIP-HSD1tg/+ islets was
abolished by UE2316 (Fig. 4I), conﬁrming enzyme speci-
ﬁcity. The increased ERK phosphorylation in MIP-HSD1tg/+
islets was also abolished in the presence of the PKA in-
hibitor KT5720 (Fig. 4J), as expected.
11b-HSD12/2 mice have mildly impaired b-cell function
offset by improved glucose tolerance. We next inves-
tigated whether 11b-HSD1 deﬁciency impacted GSIS with
HF feeding. 11b-HSD12/2 mice exhibited a blunted early-
phase GSIS and mild transient glucose intolerance in vivo
(Supplementary Fig. 6A and B). Note that glucose/insulin
homeostasis in 11b-HSD12/2 mice is comparable to con-
trol C57BL/6J mice when on CD (12), indicating a b-cell–
speciﬁc defect. However, insulin secretion was markedly
lower in HF-fed 11b-HSD12/2 than C57BL/6J mice in asso-
ciation with markedly improved glucose tolerance (Sup-
plementary Fig. 6C and D), suggesting substantially reduced
secretory demand from b-cells due to the dominant pro-
tection from glucose intolerance in HF-fed 11b-HSD12/2
mice.
Partially impaired insulin secretion in MIP-HSD1tg/tg
mice indicates a threshold effect for 11b-HSD1–
mediated b-cell compensation. Glucocorticoids some-
times show complex dose-related effects (31) (Fig. 3H). To
address this, we analyzed insulin secretion in homozygous
MIP-HSD1tg/tg mice with ;16-fold higher islet 11b-HSD1
mRNA and;4-fold higher 11b-HSD1 activity (Supplementary
Fig. 7A and B). In contrast to MIP-HSD1tg/+, MIP-HSD1tg/tg
mice exhibited a signiﬁcant reduction of whole pancreas
insulin content and marked suppression of GSIS on nor-
mal diet in vivo, although normal glucose tolerance was
BFA/CHX in 2.8 mmol/L glucose in order to stop both neosynthesis of insulin and neoformation of newly formed insulin vesicles. *P < 0.05, MIP-
HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. ††P < 0.01, treated MIP-HSD1tg/+ HF vs. treated MIP-HSD1tg/+ CD. n = 4. G: PSIS from islets of KsJ and MIP-
HSD1tg/+ mice on CD or HF diet incubated for 30 min in 2.8 mmol/L glucose and then 30 min with 40 mmol/L KCl. *P< 0.05, MIP-HSD1tg/+ HF vs. KsJ
HF. n = 6. H: GSIS from islets of KsJ and MIP-HSD1tg/+ mice on CD or HF diet preincubated for 2 h with 20 nmol/L 11-DHC (left) or 200 nmol/L
11-DHC (right) with or without 1 mmol/L UE2316 or 1 mmol/L RU486 before incubation for 30 min with 2.8 mmol/L glucose followed by 30 min with
16.8 mmol/L glucose. *P< 0.05, MIP-HSD1tg/+ HF vs. Ksj HF. †P< 0.05, MIP-HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. §P< 0.05, MIP-HSD1tg/+ HF treated vs.
MIP-HSD1tg/+ HF. n = 5–6. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 4. Validation of selected genes changes from microarray functional clusters at the mRNA, protein, and protein phosphorylation level asso-
ciated with improved islet function in HF-fed MIP-HSD1tg/+. Prkacb (A), hspa1b (B), Braf (C), and Cdkn1a (D) mRNA expression was measured
in isolated islets of KsJ and MIP-HSD1tg/+ mice on CD or HF diet and normalized to gene expression of actin. *P< 0.05; ***P< 0.001, MIP-HSD1tg/+
HF vs. KsJ HF. #P< 0.05, KsJ HF vs. KsJ CD. †P< 0.05, ††P< 0.01, MIP-HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. n = 6–8 (2–3 mice per islet preparation).
AU, arbitrary units. Isolated islets from KsJ and MIP-HSD1tg/+ mice on CD or HF diet were incubated in the absence (E and H) or presence of
1 mmol/L of the selective 11b-HSD1 inhibitor UE2316 (F and I) or 5 mmol/L PKA inhibitor KT5720 (G and J) for 24 h. Total extracts were subjected
to immunoblotting analysis for PKAb catalytic subunit and b-actin (loading control) (E–G), thr202/tyr204ERK1/2 phosphorylation, and ERK1/2
native protein (H–J). Representative images of the blots are shown above the quantiﬁcation. Quantitative analysis shows protein expression level
normalized to the respective control proteins and then expressed relative to the values in the KsJ control mice. Note that proteins from CD mice
were run on separate gels from HF mice together with the same internal control, which allowed signal comparison. *P < 0.05; **P < 0.01, MIP-
HSD1tg/+ HF vs. KsJ HF. †P < 0.05; ††P < 0.01; †††P < 0.001, MIP-HSD1tg/+ HF vs. MIP-HSD1tg/+ CD. #P < 0.05; ###P < 0.001, KsJ HF vs. KsJ CD.
§P < 0.05; §§§P < 0.001, MIP-HSD1tg/+ CD vs. KsJ CD. n = 6.
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maintained (Supplementary Fig. 7C, D, and F). However,
MIP-HSD1tg/tg mouse GSIS was comparable to littermates
on HF diet (Supplementary Fig. 7E, left, and F, left),
reﬂecting a relative improvement in GSIS versus CD, and
this partially normalized glucose tolerance (Supplemen-
tary Fig. 7E, right, and F, right). In agreement with this
intermediate phenotype, GSIS from isolated islets of HF-
fed MIP-HSD1tg/tg mice showed a higher basal and peak
secretion, although this was not sustained over the whole
second phase (Supplementary Fig. 7F).
Islet 11b-HSD1 level is predictive of b-cell compensatory
capacity and diabetes susceptibility in mice. Consid-
ering the inverted U-shaped MIP-HSD1 gene dose-response
effect on b-cell secretory function, we assessed islet 11b-
HSD1 protein and activity levels in contrasting models of
b-cell failure (HF-fed KsJ and Lepdb/db mice) and b-cell
compensation (C57BL/6J mice). HF induced a modest el-
evation of 11b-HSD1 in islets from robustly compensating
C57BL/6J mice (Fig. 5A and B). In contrast, down-
regulation of islet 11b-HSD1 was found in b-cell failure–
susceptible, HF-fed KsJ mice (Fig. 5C and D). Markedly
high 11b-HSD1 levels were found in diabetic Lepdb/db islets
(Fig. 5E and F).
DISCUSSION
Our data show that, for the ﬁrst time, an unexpectedly
beneﬁcial metabolic outcome results from optimal eleva-
tion of b-cell 11b-HSD1, in contrast to the diabetogenic
effects of elevated 11b-HSD1 in adipose tissue and liver
(3). Moreover, this effect may be physiologically relevant,
as normal mice that exhibit robust compensatory insulin
secretion on HF exhibit a similar modest upregulation of
b-cell 11b-HSD1. A higher or lower 11b-HSD1 level sup-
presses GSIS, consistent with an inverted U-shaped dose-
response effect sometimes seen with glucocorticoids (31).
This notion is supported by the stimulatory effect of physio-
logical 11b-HSD1 substrate (11-DHC) but suppressive
effects of high or indeed long-term exposure to 11-DHC
in vitro. In agreement, diabetic Lepdb/db mice (32) and
MIP-HSD1tg/tg on CD have impaired GSIS in vivo associated
with more marked elevation of b-cell 11b-HSD1. These data
are also consistent with the association between increas-
ing 11b-HSD1 levels and the severity of hyperglycemia in
diabetic fa/fa rats (5). Conversely, 11b-HSD12/2mice on CD
and KsJ mice on HF diet have b-cell secretory defects
associated with the absence or decrease of 11b-HSD1 ac-
tivity, respectively. These ﬁndings may have implications
FIG. 5. Islet 11b-HSD1 protein and activity levels relate to b-cell compensation in different mouse strains. Representative images showing 11b-
HSD1 localization throughout the islet (largely b-cells) by immunohistochemistry in pancreas from C57BL/6J mice that exhibit compensatory
insulin secretion (A), b-cell failure–prone KsJ on either CD or HF diet (C), and control KsJ wild-type or diabetic KsJ-Lepdb/db mice (E). Original
magniﬁcation340. np, no primary antibody control. Proportionately altered 11b-HSD1 activity was conﬁrmed in isolated islets from the respective
models: C57BL/6J (B) and KsJ (D) on either CD or HF diet. *P < 0.05; n = 3. ***P < 0.001; n = 9. F: KsJ wild-type and diabetic KsJ-Lepdb/db mice.
***P < 0.001; n = 6. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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for the timing and dose of steroid or 11b-HSD1 inhibitor
interventions in the therapeutic treatment of patients pre-
disposed to b-cell failure. Deﬁning the impact of altered
islet 11b-HSD1 expression across the progression from
glucose intolerance, prediabetes, and frank diabetes in both
rodent models and humans, relative to peripheral tissue
11b-HSD1 levels, will be of future importance to assess
any adverse risks of therapeutic inhibition. However, the
dominant protection from glucose intolerance found in HF-
fed 11b-HSD12/2 mice indicates that beneﬁcial effects of
11b-HSD1 inhibition may outweigh any detrimental effect
on b-cells.
The gene-dose, inverted-U effect of the MIP-HSD1 trans-
gene may reconcile conﬂicting reports of suppressive (4–8)
versus stimulatory effects (33–35) of glucocorticoids on
insulin secretion. Thus, the prevailing effect is likely a
function of dose and duration. Indeed, although our in
vitro data are generally supportive of our in vivo ﬁndings,
we note that long-term, but not short-term, static incubation
with low 11-DHC is suppressive. We contend that static
incubation with steroids and isolated islets in vitro does not
reﬂect dynamic glucocorticoid exposure/metabolism pat-
terns found in vivo. This merely serves to underline the
importance of studying the impact of altered b-cell 11b-
HSD1 in the whole animal chronic disease context. Of
note, b-cell–speciﬁc GR overexpression (RIP-GR) causes
direct suppression of insulin secretion (7). Beyond expo-
sure and dose issues, this suggests that MIP-HSD1 effects
could result from additional effects beyond GR activation.
For example, physiological corticosterone binds with high
afﬁnity to mineralocorticoid receptors, which antagonizes
GR-mediated suppression of insulin secretion and may
thus contribute to beneﬁcial (36) and dose-sensitive effects.
Notably, the synthetic GR-selective glucocorticoid dexa-
methasone, commonly used in in vitro islet studies, is a
poor 11b-HSD1 substrate, perhaps further explaining dif-
ferences between solely GR- versus 11b-HSD1–mediated
effects in islets. 11b-HSD1 reductase activity depletes en-
doplasmic reticulum (ER) NADPH, but this does not appear
to affect the increased cytosolic NADPH levels required to
activate GSIS (37). Elevated 11b-HSD1 may also prefer-
entially amplify nongenomic effects of glucocorticoids (38)
more than GR overexpression, or indeed non-GR effects
due to alternative substrate metabolism (39) by 11b-HSD1.
Indeed, alternate 11b-HSD1 metabolites (40) may affect
GSIS through oxysterol activation of nuclear liver X re-
ceptor (41). Finally, RIP-GR mice may manifest impaired
GSIS as a result of developmentally impaired b-cell mass
(20), unlike the MIP-HSD1 model. In any case, there is more
evidence to suggest that islet 11b-HSD1, rather than GR,
levels are elevated in islets from diabetic mice (5,6, and the
current study), suggesting the MIP-HSD1 mice are perhaps
a more relevant in vivo model. Crucially, the unexpected
augmentation of GSIS in the MIP-HSD1 mice due to chronic
modest elevation of b-cell 11b-HSD1 in vivo has allowed
us to challenge prevailing hypotheses on glucocorti-
coid-mediated diabetogenic effects in islets. Those hy-
potheses are derived from arguably artiﬁcial systems such
as systemic administration of high-dose steroids in vivo,
which induces confounding peripheral insulin resistance, as
well as the effects of acute and often pharmacological ste-
roid concentrations in islets in vitro.
Elevated expression of genes involved in differentiation,
insulin secretion, and cellular stress protection and survival
are associated with augmented MIP-HSD1tg/+ islet function.
Although similar effects of glucocorticoids have been noted
in other cellular systems, our data show these effects for the
ﬁrst time, to our knowledge, in pancreatic islets, and high-
light novel areas of cross-talk in this cell type. Thus, glu-
cocorticoids curtail proliferation and induce differentiation,
in part through the increased cyclin-dependent kinase in-
hibitor 1A (p21) (24,26,27,42) and enhanced differentiation
through ERK1/2 (26). Increased v-raf murine sarcoma viral
oncogene homolog B1 (B-Raf) signaling (43) and enhanced
PKAbcat and small GTPase activation makes a clear
mechanistic link with augmented insulin secretory capacity
(21,25,43) as well as islet survival in the face of HF diet–
induced ER stress (23); chronic exposure to elevated NEFA
was comparable between genotypes, indicating a b-cell–
speciﬁc protection from lipotoxicity in the MIP-HSD1tg/+
mice. In contrast, we ﬁnd a novel permissive role for 11b-
HSD1 in short-term, fatty acid–induced GSIS in vitro, sug-
gesting a physiological role for 11b-HSD1 in meal lipid–
related GSIS processes. Further, a direct interaction between
GR and PKA has been proposed in other cellular systems
(40,44), suggesting a novel mechanism for functional aug-
mentation of b-cells that can now be fully explored. Heat
shock protein induction is consistent with increased GR
activation (45,46) and, along with p21 in islets (29), is associ-
ated with cell survival and protection from apoptosis (28,47),
echoing critical processes activated in b-cells that success-
fully adapt to ER stress (30,45). Note the impact of elevated
11b-HSD1 on b-cell apoptosis will need careful future ex-
ploration in model systems other than the HF-fed C57BL/KsJ
mice where this process is more evident and quantiﬁable.
Notably, we did not ﬁnd suppression of inﬂammatory pro-
cesses linked to islet damage in type 2 diabetes (48), as
occurs when islets are exposed to high levels of corticoste-
rone (45), perhaps reﬂecting the more physiological nature of
b-cell protection in our model. The data therefore give insight
into a novel mechanistic framework whereby optimally ele-
vated local glucocorticoid action may facilitate safe execu-
tion of increased secretory demand, thus avoiding b-cell
failure. Of particular note, given the topical nature of repli-
cation as a mechanism for compensation (49,50), the novel
protective response of MIP-HSD1tg/+ mice does not involve
increased b-cell replication. Intriguingly, despite suppressed
MIP-HSD1tg/tg islet function under basal (CD) conditions, the
markedly elevated b-cell 11b-HSD1 of MIP-HSD1tg/tg elicits
an HF diet–responsive b-cell rescue response that is ade-
quate enough to normalize glucose homeostasis. This sug-
gests the potential for mechanistic dissection of therapeutic
glucocorticoid effects from those that are undesirable.
Transgenic elevation of b-cell 11b-HSD1 has revealed a
novel physiological function for the enzyme in b-cell com-
pensation that may open up new therapeutic opportunities.
More broadly, coordinated regulation of local glucocorti-
coid regeneration in b-cells with dynamic changes in adi-
pose tissue delineates a responsive physiological process
that shapes metabolism to protect against metabolic dis-
ease. Of more immediate medical signiﬁcance, our data
critically inform imminent therapeutic strategies aimed at
manipulation of tissue glucocorticoid action.
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